Othman Salim Akhtar - Concepedia

Author

Othman Salim Akhtar

Medical College of Wisconsin ORCID

Also Known As

O. Akhtar, Othman Akhtar, Othman S Akhtar, Othman S. Akhtar, Othman Salim Akhtar

Publications

567

Citations

H-Index

Concepts

All Affiliations

Medical College of Wisconsin Medical University of South Carolina Roswell Park Comprehensive Cancer Center Moffitt Cancer Center Memorial Sloan Kettering Cancer Center

About

Othman Salim Akhtar is an author at Medical College of Wisconsin specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	106
2	Immunology	3	3	83
3	Pathology	1	1	23
4	Pharmacology	1	1	40
5	Vascular Surgery	1	1	23

Othman Salim Akhtar

Publications

275

Citations

H-Index

Page 1

	Year	Citations
Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research Registry Rachel Cusatis, Carlos Litovich, Zhongyu Feng, Transplantation and Cellular Therapy	2024	61
Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL) Othman Salim Akhtar, Kristopher Attwood, Ian Lund, Leukemia & lymphoma/Leukemia and lymphoma Hematological MalignancyLymphoid NeoplasiaDose ReductionsMedicineInferior Outcomes	2019	40
Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, Blood	2023	29
Contemporary Trends and Comparative Outcomes With Adjunctive Inferior Vena Cava Filter Placement in Patients Undergoing Catheter-Directed Thrombolysis for Deep Vein Thrombosis in the United States Othman Salim Akhtar, Vladimir Lakhter, Chad Zack, JACC: Cardiovascular Interventions Pulmonary EmbolismThrombosisCatheter-directed ThrombolysisVenous ThrombosisMedicine	2018	23
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma Yazeed Sawalha, Subir Goyal, Jeffrey M. Switchenko, Blood Advances Venetoclax MonotherapyLymphoid NeoplasiaDisease RelapseHematological MalignancyMulticenter Analysis	2023	23
Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy Othman Salim Akhtar, Karnav Modi, Jongphil Kim, Transplantation and Cellular Therapy Hematological MalignancyOncologySimple ScoreMalignant Blood DisorderImmunology	2023	20
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma Meera Mohan, Oliver Van Oekelen, Othman Salim Akhtar, American Society of Clinical Oncology Educational Book	2024	18
Frequency and timing of other primary cancers in patients with chronic lymphocytic leukemia (CLL): a 17-year longitudinal study Othman Salim Akhtar, Adrienne Groman, Anil Singh, Leukemia & lymphoma/Leukemia and lymphoma	2022	16
Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Binod Dhakal, Othman Salim Akhtar, Andrew J. Cowan, Blood	2024	13
Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention Fateeha Furqan, Vineel Bhatlapenumarthi, Binod Dhakal, Blood Advances	2024	12

Page 1